News | June 03, 2013

This is the third Mevion S250 proton therapy system delivered


June 3, 2013 — Mevion Medical Systems has delivered the superconducting synchrocyclotron accelerator for its Mevion S250 proton therapy system under installation at the Peggy and Charles Stephenson Cancer Center at the University of Oklahoma.

This is the third single-room Mevion S250 proton therapy system delivered — all installed at leading academic institutions.

”We are delighted to receive this revolutionary machine that will allow us to deliver the same proton treatment as other larger conventional systems but at a fraction of the cost and size and with the most advanced clinical targeting technology” said Mike Samis, chairman of the University Hospitals Authority and Trust. “The addition of this advanced treatment option to our flagship cancer center continues to define the OU Cancer Institute as the state’s leading center of excellence.”

Following a five-day journey from Massachusetts to Oklahoma, the proton accelerator was brought into the Stephenson Cancer Center in only a few hours and will be installed on its gantry. The Mevion S250 is enhancing the center’s state-of-the-art radiation therapy department with a fully integrated proton therapy clinical treatment room. A second Mevion S250 treatment space has been reserved to support future clinical demand.

Powered by a TriNiobium Core, the Mevion S250 is a unique proton therapy system that provides the same precise, non-invasive treatment capabilities and advantages of conventional systems but with significantly reduced size, improved reliability, efficient clinical workflow and lower implementation and operational costs. With a footprint similar to an X-ray radiation therapy device, Mevion proton therapy can be easily integrated into any existing radiation therapy department.

For more information: www.mevion.com


Related Content

News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Subscribe Now